Reported results
- Total revenue was $23.1 million in the third quarter of 2026.
- RNS System revenue was $22.9 million in the third quarter of 2026.
- Non-GAAP gross margin for the third quarter of 2026 was 84.8%.
- Total GAAP gross margin from continuing operations in the third quarter of 2026 was 84.3%.
- Non-GAAP operating expenses in the third quarter of 2026 were $19.2 million.
- Adjusted EBITDA was $0.4 million for the third quarter of 2026.
Guidance
- Full year 2026 total revenue guidance of $91 million to $92 million.
- Full year 2026 non-GAAP gross margin guidance of 83.0% to 83.5%.
- Full year 2026 non-GAAP operating expenses guidance of $85 million to $86 million.
- Full year 2026 Adjusted EBITDA guidance of ($8.5) million to ($9.5) million.
Notes
The Company’s DIXI Medical product operations are presented as discontinued operations; prior-period amounts have been reclassified on a comparable basis.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.
